Should Value Investors Buy Vinci (VCISY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Vinci Compass Investments Q2 Earnings Call Highlights
Vinci Compass Investments NASDAQ: VINP reported second-quarter 2026 fee-related earnings of BRL 88.7 million, or BRL 1.35 per share, as management fees increased and the firm benefited from acquisitions and organic fundraising. The alternative asset manager's fee-related earnings margin reached 32.5%, while adjusted distributable earnings were BRL 63.3 million, or BRL 0.96 per share.
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.
Vinci SA (VCISY) Q2 2026 Earnings Call Transcript
Vinci SA (VCISY) Q2 2026 Earnings Call Transcript
Vinci Compass Will Face A Challenging Period With Lower Liquidity (Downgrade)
Vinci Compass (VINP) is downgraded to Hold due to deteriorating earnings quality and shrinking core private equity operations. Headline FRE margin improvement is largely inorganic, driven by the Verde acquisition, with underlying owner FRE margin closer to 33%. Private Equity AUM and management fees continue to decline, with no new capital raised and significant capital returns over the past year.
Vinci SA (VCISY) Shareholder/Analyst Call Transcript
Vinci SA (VCISY) Shareholder/Analyst Call Transcript
Vinci: There Are Better Value Infrastructure Plays Out There
Vinci SA benefits from strong concessions performance and robust growth in its energy business, especially from electrification infrastructure trends. Airport concessions, notably in Japan and Budapest, are seeing solid growth driven by tourism and FX trends, with Gatwick capacity set to rise 33%. Highway revenues are supported by tariff increases, though underlying traffic growth is modest and margins face pressure from depreciation on French projects.
Intuitive Surgical Poised for Growth in 2026 on da Vinci 5 Momentum
ISRG rides da Vinci 5 momentum as procedure volumes surge, global adoption expands and Ion and SP platforms boost recurring revenue growth into 2026.
Vinci SA (VCISY) Q4 2025 Earnings Call Transcript
Vinci SA (VCISY) Q4 2025 Earnings Call Transcript
da Vinci 5 Expands Globally: Can ISRG Beat Overseas Cost Hurdles?
ISRG's da Vinci 5 begins international rollout, but pricing sensitivity, budgets, and reimbursement hurdles could slow adoption outside the United States.
Can da Vinci 5 Expand Intuitive Surgical's TAM Beyond Core Surgeries?
ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.
Intuitive Surgical: Da Vinci Delivers, Double-Digit EPS Growth, Golden Cross
Intuitive Surgical delivered robust Q3 results, with 23% revenue growth and a significant double beat on EPS and revenue. ISRG's valuation remains lofty, trading near fair value despite strong growth and a bullish golden cross technical setup. I maintain a "Hold" rating on ISRG, citing premium multiples, fair value, and technical resistance near $600.
